Pharma Focus America
ThermoFisher Scientific - Go beyond the catalog

First North American Biomanufacturing Facility Opened in USA by WuXi Biologics

Introduction:

WuXi Biologics opened MFG18, its first GMP phase I drug substance clinical production facility, in Cranbury, New Jersey, USA.

Features:

With solely single-use technology, the 154,448 square foot site's operational capacity for clinical manufacture will increase to 6,000 litres from its initial capacity of 4,000 litres.

The plant, which was built in response to the expanding demand of customers around the world, is WuXi Bio's first GMP manufacturing facility in North America.

The site plays a crucial role in WuXi Biologics' global dual sourcing strategy, which makes it possible for products to be produced and materials to be sourced at various WuXi Biologics locations across the globe.

When fully operational, the facility will have over 250 personnel, up from over 150 at the moment.

Specifications:

NameWuXi Biologics
TypeNew Construction

 

Sartorius Lab Balance CleaningFestival of Biologics San Diego 2024Equinix accelerated medical research...World Vaccine Congress Europe 2024World Orphan Drug Congress 2024World Vaccine Congress Washington 2024Future Labs Live USA 2024Interphex 2024Pharma USA 2024